Target Identification for TPD Development
* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
Target identification is the earliest and most consequential decision in every targeted protein degradation (TPD) research program. Whether a team starts from a disease hypothesis, a known protein of interest, or a bioactive small molecule with an unexplained phenotype, the same question must be answered first: which protein should be degraded, and is it genuinely suitable for a degrader? BOC Sciences provides integrated target identification services for TPD development, combining functional genomics, quantitative proteomics, chemoproteomics, and computational modeling to discover, deconvolute, and prioritize degradation-competent targets. Our scientists help you move from a broad candidate landscape to a short list of well-characterized proteins with clear evidence of disease relevance, ligand accessibility, and E3 ligase compatibility, so that downstream PROTAC design services begin from a stronger scientific foundation.
Request a Consultation Explore ServicesServices
BOC Sciences Target Identification Services for TPD Development
Disease-Associated Protein Target Discovery
We map the protein landscape of a given disease and identify targets that are causally linked to the phenotype rather than merely correlated with it. By integrating genetic dependency data, expression profiles, pathway analysis, and literature evidence, we help you separate true disease drivers from bystanders and define a focused candidate set for degradation. This is often the entry point for teams that know their disease area but have not yet committed to a specific protein of interest, and it connects directly to our broader target protein services.
Functional Genomics-Based Target Identification
We use genome-wide and targeted CRISPR and RNAi perturbation to connect genes to cellular phenotypes and reveal which proteins a disease cell truly depends on. Loss-of-function and gain-of-function formats, together with resistance and sensitization designs, identify genuine vulnerabilities that can be translated into degradation strategies. Screening collections can be aligned with specific pathways, gene families, or disease contexts through our customizable screening library.
Proteomics-Guided Target Identification
Quantitative mass spectrometry provides a direct readout of which proteins change in abundance, interaction, or modification across disease states or treatments. We combine global proteomics, interaction proteomics, and ubiquitin-focused profiling to surface candidate targets and to confirm that they are expressed, dynamically regulated, and degradable in the relevant cellular context.
Phenotypic Hit Target Deconvolution
When a compound produces a strong phenotype but its molecular target is unknown, we identify the responsible protein and confirm that the compound engages it directly. Phenotypic screening, affinity-based enrichment, and competition experiments connect the small molecule to its target and clarify whether the interaction is specific and functionally relevant.
Molecular Glue Neo-Substrate Identification
Molecular glues and monovalent degraders redirect an E3 ligase toward substrates that are not obvious from structure alone. We combine proteome-wide degradation profiling with interaction analysis to identify neo-substrates, distinguish intended degradation from collateral protein loss, and help you decide whether a glue-like mechanism is a productive route for your program, supported by our dedicated molecular glue technology development capabilities.
TPD Target Candidate Prioritization
Candidates are ranked against TPD-specific criteria such as disease relevance, protein turnover, structural ligandability, surface lysine availability, and E3 ligase compatibility. The output is a transparent, evidence-weighted short list that guides which protein to pursue first and how it should be carried into PROTAC design for target proteins.
Not Sure Which Target to Take Forward?
From disease-associated target discovery to chemoproteomic deconvolution, we help you define and defend the protein that deserves your next degrader program.
Platforms
Technical Platforms for TPD Target Identification
CRISPR and RNAi Screening
Genome-scale and focused perturbation screens identify the genes and proteins that a disease cell depends on, providing the genetic evidence that anchors target selection. Positive-selection, negative-selection, and resistance formats can be combined to distinguish drivers from passengers.
- CRISPR knockout, CRISPR interference (CRISPRi), and CRISPR activation (CRISPRa) screens
- siRNA and shRNA knockdown libraries
- Pathway-focused, druggable-genome, and custom panels with resistance and sensitization readouts
Transcriptomics and Gene Expression Analysis
Gene expression profiling reveals which proteins are selectively expressed in a disease state and how signaling networks respond to perturbation, helping to define target context and tractability. Our PROTAC design based on bioinformatics integrates these datasets with degrader design logic.
- RNA sequencing and differential expression analysis
- Pathway and network enrichment for candidate targets
- Expression-based E3 ligase and substrate compatibility screening
Quantitative Mass Spectrometry-Based Proteomics
Label-free and labeled quantitative proteomics measures real protein-level changes rather than transcript-level predictions. When integrated with protein ubiquitination services, it can pinpoint proteins whose degradation is driven by the ubiquitin-proteasome system.
- Global proteome profiling across disease models and treatments
- Ubiquitinomics for ubiquitination-dependent candidate discovery
- Dose- and time-resolved profiling to confirm direct effects
Chemical Proteomics and Protein Interaction Mapping
Interaction mapping establishes which proteins a compound physically engages, which is essential for phenotypic hit deconvolution. We apply affinity enrichment and competition approaches, and confirm direct binding through binding affinity measurement.
- Affinity enrichment mass spectrometry for target engagement
- Small-molecule interaction and competition profiling
- Direct versus indirect binder discrimination
Turn Target Hypotheses into Actionable Candidates
Connect genomics, proteomics, and interaction data into one integrated target identification campaign.
Advantages
Why Target Identification Is Critical for TPD Development?
Overcoming the Druggable Proteome Limitation
Most human proteins lack a conventional druggable pocket. By selecting targets that suit degraders rather than inhibitors, programs can reach proteins previously considered inaccessible, as enabled by ubiquitin-proteasome based degradation technology.
Reducing Late-Stage Attrition in Degrader Programs
Choosing the wrong protein, or the wrong degron, can waste months of synthesis and assay work. Early feasibility assessment and PROTAC off-target evaluation help identify risks before they become program-ending.
Enabling Rational E3 Ligase and Linker Decisions
Knowing which lysines are exposed and which ligases are expressed guides recruiter choice and linker geometry, supported by ligand design for E3 ligase and structural insight.
Strengthening Disease, Target, and Modality Relevance
Documented disease causality, suitable expression, and degradation compatibility create a defensible scientific rationale that aligns project teams and supports confident go/no-go decisions.
Applications
Applications of Target Identification in TPD Development
Transcription Factors and Chromatin Regulators
Many oncogenic transcription factors and chromatin readers lack enzymatic pockets, which makes them ideal degradation targets. We identify dependency-linked regulators and confirm whether they can be engaged, for example in PROTAC targeting BRD4 and related chromatin programs.
Scaffold Proteins and Protein Complex Components
Scaffold and adaptor proteins organize signaling complexes but often resist inhibition. Degrading a scaffold can collapse an entire complex, and target identification helps determine which component provides the strongest therapeutic effect, as explored in PROTAC targeting FAK.
Oncogenic Fusion Proteins and Mutant Targets
Fusion and mutant proteins drive many cancers but are difficult to inhibit selectively. We identify fusion-derived targets and assess whether the chimera presents a degradable surface, illustrated by PROTAC targeting ALK.
Disease-Associated Signaling and Regulatory Proteins
Kinases, phosphatases, and regulatory proteins that lack inhibitor-suitable pockets can be addressed through degradation. We prioritize candidates by dependency and tractability across kinase families, as in PROTACs targeting protein kinases.
Have a Specific TPD Application in Mind?
If you have a specific research application in mind, BOC Sciences offers tailored target identification solutions to help you achieve your research goals and advance your TPD development projects.
Workflow
Our TPD Target Identification Workflow
01
Project Scoping and Entry-Pathway Definition
We discuss your starting point, disease context, available compounds or datasets, and program goals to define whether the project is best approached as target-first, ligand-first, or phenotype-first.
02
Disease Context and Target Landscape Mapping
We build a candidate landscape from genetic, expression, pathway, and literature evidence to identify the proteins most likely to drive the disease phenotype.
03
Multi-Omics Mining and Candidate Prioritization
Genomics, transcriptomics, and proteomics datasets are integrated to rank candidates by dependency, expression, and turnover, narrowing the list toward the most promising proteins.
04
Ligandability and Druggability Assessment
Structural analysis, pocket detection, and ligand discovery, including virtual screening, determine whether each candidate can be engaged by a binder that is suitable for degrader design.
05
Chemoproteomic Deconvolution and Engagement Validation
When a compound is involved, affinity enrichment and competition experiments identify its direct protein target and confirm specific engagement before that protein is advanced.
06
E3 Ligase Pairing and Ternary Complex Simulation
We match candidate targets with compatible E3 ligases and model ternary complex geometry, then test feasibility with a PROTAC ternary complex assay.
07
Experimental Validation and Mechanism Confirmation
Degradation is verified by a degradation ability assay and orthogonal methods, confirming that the target is lost through the intended mechanism.
08
Data Integration and Optimization Guidance
All evidence is consolidated into a ranked target report with clear recommendations on which protein to pursue and how to approach the subsequent degrader design.
Start Your Target Identification Project
Share your target, disease area, or compound and receive a tailored study design with a clear, evidence-based path forward.
Why Us
Why Choose BOC Sciences for TPD Target Identification?
Multiple Discovery Strategies for Different Research Needs
We support target-first, ligand-first, and phenotype-first programs with the appropriate combination of genomics, proteomics, and chemistry, rather than forcing every project into a single template.
Integration of Disease Biology and TPD-Specific Insights
Our recommendations combine disease biology with degrader-specific thinking, including ligase pairing, ternary complex feasibility, and structural assessment, so the science holds up beyond the initial screening result.
Complementary Technologies for Reliable Target Identification
Genomics, mass spectrometry, chemical proteomics, and structural analysis, including protein-ligand structure analysis, cross-validate each other and reduce the risk of false-positive targets.
Customized Research Plans and Actionable Target Recommendations
Every project receives a customized plan and a decision-ready report, with follow-up support that connects target selection to linker design and optimization services.
Integrated Downstream TPD Support
Target identification is not an isolated step. It connects directly to design, synthesis, degradation testing, and mechanism assays within one coordinated workflow.
Clear, Decision-Ready Reporting
Instead of a raw data dump, we deliver ranked candidates with the reasoning, confidence level, and experimental next steps that your team needs to act.
Case Study
Case Studies: Target Identification for TPD Development
Project Background
A Canadian biotechnology company observed that a subset of gastric cancer models depended on a poorly characterized transcriptional regulator, but the team could not tell which protein in an amplified genomic region was the true driver. Before committing to a degrader program, they needed to convert a broad disease-dependency signal into a single, well-defined, degradation-competent target.
Technical Challenges
The amplified region contained several candidate genes, and correlation alone could not separate the driver from passenger proteins. There was limited structural and ligand information for the leading candidates, and it was unclear whether the most dependent protein would be accessible to a degrader or compatible with an available E3 ligase.
BOC Sciences Solutions
- Functional Genomics Screening: We performed genome-wide CRISPR knockout and CRISPRi screens across matched sensitive and resistant cell lines, probing approximately 19,000 genes to identify dependencies that tracked with the disease phenotype.
- Multi-Omics Integration: Transcriptomic, copy-number, and proteomic data were combined to prioritize candidates with consistent overexpression, detectable protein abundance, and strong dependency scores.
- TPD-Specific Tractability Assessment: The top candidates were evaluated for ligandable regions, surface lysine accessibility, and E3 ligase compatibility to determine which protein could realistically be degraded.
Project Outcomes
From an initial pool of 23 candidate genes, BOC Sciences narrowed the field to a single prioritized transcriptional regulator that showed the strongest and most reproducible genetic dependency, adequate protein abundance, a partially structured and ligand-accessible region, and exposed surface lysines suitable for CRBN-based degradation. Two backup targets were retained for parallel monitoring. The client used this prioritized target to launch a degrader program and, building on the workflow, moved into PROTAC degradation technology development with a target rationale they could defend internally.
Project Background
A US-based pharmaceutical research group had a small molecule that produced a strong anti-proliferative phenotype through a CRBN-dependent mechanism, yet the protein that was actually degraded remained unknown. The team wanted to identify the responsible neo-substrate and confirm whether the mechanism could guide a new glue-based program.
Technical Challenges
The compound bound CRBN weakly, and the candidate substrate was of low abundance, making it difficult to separate direct degradation from downstream abundance changes. An initial proteomic experiment returned several proteins with reduced levels, and the team needed a way to determine which, if any, was the true direct neo-substrate.
BOC Sciences Solutions
- Ligase-Dependent Proteome Profiling: We performed dose- and time-resolved proteomics at four concentrations and three time points, using CRBN knockout controls to confirm that any depletion depended on the ligase.
- Comparative Ubiquitinomics: Proteins showing increased ubiquitination after treatment were identified, filtering the candidate list toward genuinely ubiquitin-driven events.
- Interaction and Structural Validation: Chemoproteomic enrichment and competition experiments tested direct, dose-dependent engagement, and structural modeling assessed whether a credible ternary interface could form.
Project Outcomes
From an initial set of nine proteins with reduced abundance, BOC Sciences identified two ligase-dependent candidates, and only one showed direct, dose-dependent ternary engagement together with a structurally plausible CRBN interface. This protein was confirmed as the primary neo-substrate. The layered filtering approach, combining abundance, ubiquitination, interaction, and structural evidence, reduced false positives and gave the client a mechanistic basis to design next-generation analogs, supported by our CRBN-based PROTAC development platform.
Frequently Asked Questions (FAQ)
Can target identification begin without a known protein target?
Yes. TPD target identification does not require a predefined protein target. Researchers can begin with a disease area, relevant cellular models, or phenotypic screening results. Functional genomics, transcriptomics, and quantitative proteomics can help identify proteins associated with disease mechanisms and cellular dependencies. BOC Sciences integrates CRISPR screening, disease relevance analysis, protein expression profiling, and preliminary ligandability assessment to identify and prioritize potential targets. However, disease association alone does not establish that a protein can be effectively degraded. Additional functional validation and degradability studies may be needed to determine whether prioritized proteins are suitable candidates for further targeted protein degradation research.
How are targets identified from bioactive small molecules?
Bioactive small molecules with unknown protein targets can be investigated using chemical proteomics, affinity-based enrichment, thermal stability profiling, and mass spectrometry. The most suitable strategy depends on compound structure, chemical modification feasibility, cellular activity, and available experimental data. Affinity enrichment can reveal proteins that interact with a compound, while cellular thermal shift assays and thermal proteome profiling provide evidence of potential target engagement in a cellular environment. BOC Sciences combines complementary approaches with competition experiments, orthogonal assays, and functional analysis to narrow candidate lists. This integrated strategy helps researchers distinguish likely direct protein targets from indirect biological responses and evaluate their relevance to subsequent TPD molecule design.
How can molecular glue degradation substrates be distinguished?
Molecular glue degraders can promote interactions between specific proteins and E3 ubiquitin ligases, resulting in degradation of proteins that may not otherwise be recruited. Quantitative proteomics is commonly used to identify proteins showing reduced abundance following compound treatment. However, reduced protein levels alone do not establish direct degradation. Researchers should also examine concentration-dependent and time-dependent responses, proteasome involvement, and E3 ligase dependency. BOC Sciences can integrate these findings with targeted protein analysis, protein interaction studies, and mechanism-focused control experiments. This approach helps distinguish potential direct degradation substrates from proteins affected by downstream cellular responses, providing stronger mechanistic evidence for molecular glue characterization and optimization.
What criteria help prioritize potential TPD protein targets?
Selecting a promising TPD target requires evaluating both biological relevance and the feasibility of inducing protein degradation. Disease association, genetic dependency, and protein expression patterns help establish whether removing a protein may produce a meaningful biological effect. Structural characteristics, accessible ligand-binding regions, subcellular localization, and compatibility with available E3 ligase systems influence degrader design feasibility. Researchers should also consider whether eliminating the entire protein offers potential advantages over inhibiting a specific functional site. BOC Sciences integrates functional genomics, proteomics, and structural analysis to compare candidate targets across these dimensions. The resulting assessment supports informed target prioritization and helps define subsequent validation, ligand discovery, and degradability experiments.
How does BOC Sciences implement target identification projects?
BOC Sciences begins each TPD target identification project by reviewing the client's research objectives, disease context, available target information, bioactive compounds, and existing experimental data. Based on the project's starting point, our scientists develop a customized strategy covering disease-associated target discovery, small-molecule target deconvolution, or degradation substrate identification. Appropriate cellular models, functional screening methods, proteomics technologies, and confirmatory experiments are selected according to research needs. During project execution, experimental findings are integrated to refine candidate selection and guide additional investigations where necessary. The resulting research package can include candidate target lists, supporting experimental data, evidence-based prioritization, mechanistic interpretation, and recommendations for subsequent TPD development activities.
Testimonials
Client Testimonials on TPD Target Identification Services
Comprehensive Target Identification for Bioactive Small Molecules
"We had a set of bioactive small molecules with clear phenotypes but no confirmed targets. BOC Sciences mapped the interactions, confirmed the primary target, and showed which secondary signals were real. It changed how we prioritized our series."
— Dr. Baker, Head of Chemical Biology at a European Research Institute
In-Depth Insights into Phenotypic Hit Mechanisms
"The team went beyond a target list and explained the mechanism behind our phenotypic hit. Their proteomic and engagement data helped us decide which protein was worth pursuing with a degrader."
— Dr. Kelly, Senior Scientist at a US Oncology Biotech Company
Precise Identification of Molecular Glue Degradation Targets
"Identifying the neo-substrate of our glue-like molecule was the key question for our program. BOC Sciences combined proteomics and interaction studies to pinpoint the primary substrate with confidence."
— Dr. Rogers, Degradation Program Lead at a European Pharmaceutical Company
Valuable Target Identification Insights for TPD Development
"Their prioritization framework was practical. We received a ranked short list with clear reasons for each candidate, which made our internal go/no-go decision much faster."
— Ms. Allen, Project Manager at a US Biotechnology Firm
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
